There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MannKind (MNKD) and Madrigal Pharmaceuticals (MDGL) with bullish sentiments.
MannKind (MNKD)
In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on MannKind, with a price target of $6.50. The company’s shares closed last Thursday at $4.20.
According to TipRanks.com, Lichtman is a 5-star analyst with an average return of 16.1% and a 56.0% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Organogenesis Holdings, and Merit Medical Systems.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MannKind with a $6.40 average price target, implying a 59.2% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
See today’s analyst top recommended stocks >>
Madrigal Pharmaceuticals (MDGL)
Oppenheimer analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals today and set a price target of $190.00. The company’s shares closed last Thursday at $134.61.
According to TipRanks.com, Olson is a 3-star analyst with an average return of 3.0% and a 47.1% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Crispr Therapeutics AG, and Frequency Therapeutics.
Madrigal Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $172.09, a 28.9% upside from current levels. In a report issued on May 7, H.C. Wainwright also maintained a Buy rating on the stock with a $184.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.